[D- MET2 , PRO5 ]-ENKEPHALINAMIDE
Modify Date: 2024-01-12 16:17:52
![[D- MET2 , PRO5 ]-ENKEPHALINAMIDE Structure](https://www.chemsrc.com/caspic/237/63307-63-1.png)
[D- MET2 , PRO5 ]-ENKEPHALINAMIDE structure
|
Common Name | [D- MET2 , PRO5 ]-ENKEPHALINAMIDE | ||
|---|---|---|---|---|
| CAS Number | 63307-63-1 | Molecular Weight | 612.74000 | |
| Density | 1.31g/cm3 | Boiling Point | 1065ºC at 760 mmHg | |
| Molecular Formula | C30H40N6O6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 597.9ºC | |
Use of [D- MET2 , PRO5 ]-ENKEPHALINAMIDE(D-Met2,Pro5)-Enkephalinamide is a highly potent opiate agonist, and shows antinociceptive activity[1][2][3]. |
| Name | 1-[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | (D-Met2,Pro5)-Enkephalinamide is a highly potent opiate agonist, and shows antinociceptive activity[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vivo | (D-Met2,Pro5)-Enkephalinamide (intravenous injection; 0.25 and 0.5 mg/kg; once) leads to the decreasement of prolactin (PRL) secretion in lactating rats[2]. Animal Model: Wistar lactating rats[2] Dosage: 0.25 and 0.5 mg/kg Administration: Intravenous injection; 0.25 and 0.5 mg/kg; once Result: Decreased plasma PRL levels 15 min after the administration in continuously lactating rats. Produced a marked depression in plasma PRL concentration in non-deprived lactating mothers. |
| Density | 1.31g/cm3 |
|---|---|
| Boiling Point | 1065ºC at 760 mmHg |
| Molecular Formula | C30H40N6O6S |
| Molecular Weight | 612.74000 |
| Flash Point | 597.9ºC |
| Exact Mass | 612.27300 |
| PSA | 233.71000 |
| LogP | 4.12870 |
| Index of Refraction | 1.616 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
|
~%
[D- MET2 , PRO5... CAS#:63307-63-1 |
| Literature: Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
[D- MET2 , PRO5... CAS#:63307-63-1 |
| Literature: Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
[D- MET2 , PRO5... CAS#:63307-63-1 |
| Literature: Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
[D- MET2 , PRO5... CAS#:63307-63-1 |
| Literature: Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
[D- MET2 , PRO5... CAS#:63307-63-1 |
| Literature: Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
[D- MET2 , PRO5... CAS#:63307-63-1 |
| Literature: Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
[D- MET2 , PRO5... CAS#:63307-63-1 |
| Literature: Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
|
~%
[D- MET2 , PRO5... CAS#:63307-63-1 |
| Literature: Audigier; Mazarguil; Gout; Cros European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 173 - 177 |
| H-Tyr-D-Met-Gly-Phe-Pro-NH2 |
| L-tyrosyl-D-methionyl-glycyl-L-phenylalanyl-L-proline amide |
| Tyr-D-Met-Gly-Phe-Pro-NH2 |